| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = -$69,657 ) |
| | 2026 | 2023 | STINGINN, LLC | 13520 SW 99TH CT | MIAMI | FL | 33176-6117 | MIAMI-DADE | USA | R41CA275637 | Human specific STING agonists for the treatment of cancer | 000 | 1 | NIH | 4/27/2026 | -$69,657 |
|
| Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | STINGINN, LLC | 1951 NW 7TH AVE STE 600 | MIAMI | FL | 33136-1128 | MIAMI-DADE | USA | R42CA290612 | Human T Cell Lymphotropic Virus Vaccine Development | 000 | 3 | NIH | 9/17/2025 | $0 |
| | 2025 | 2023 | STINGINN, LLC | 1951 NW 7TH AVE STE 600 | MIAMI | FL | 33136-1128 | MIAMI-DADE | USA | R41CA275637 | Human specific STING agonists for the treatment of cancer | 000 | 1 | NIH | 10/18/2024 | $0 |
| | 2025 | 2022 | STINGINN, LLC | 13520 SW 99TH CT | MIAMI | FL | 33176-6117 | MIAMI-DADE | USA | R41AI167270 | Anti-inflammatory Activity of a Systemic STING Inhibitory Non-Nucleotide | 000 | 1 | NIH | 11/26/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $999,969 ) |
| | 2024 | 2024 | STINGINN, LLC | 1951 NW 7TH AVE STE 600 | MIAMI | FL | 33136-1128 | MIAMI-DADE | USA | R42CA290612 | Human T Cell Lymphotropic Virus Vaccine Development | 000 | 3 | NIH | 8/15/2024 | $999,969 |
|
| Issue Date FY: 2023 ( Subtotal = $1,681,986 ) |
| | 2023 | 2023 | STINGINN LLC | 1951 NW 7TH AVE | MIAMI | FL | 33136-1128 | MIAMI-DADE | USA | R41CA275637 | Human specific STING agonists for the treatment of cancer | 000 | 1 | NIH | 7/10/2023 | $399,812 |
| | 2023 | 2023 | STINGINN LLC | 1951 NW 7TH AVE | MIAMI | FL | 33136-1128 | MIAMI-DADE | USA | R41AI165061 | Human T cell Lymphotropic Virus Vaccine development | 000 | 2 | NIH | 1/9/2023 | $288,295 |
| | 2023 | 2023 | STINGINN, LLC | 1951 NW 7TH AVE | MIAMI | FL | 33136-1128 | MIAMI-DADE | USA | R42CA250629 | STING Activators as Therapy for Cancer | 000 | 3 | NIH | 8/23/2023 | $993,879 |
| | 2023 | 2022 | STINGINN, LLC | 1951 NW 7TH AVE | MIAMI | FL | 33136-1128 | MIAMI-DADE | USA | R41AI167270 | Anti-inflammatory Activity of a Systemic STING Inhibitory Non-Nucleotide | 000 | 1 | NIH | 8/2/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,593,080 ) |
| | 2022 | 2022 | STINGINN, LLC | 1951 NW 7TH AVE STE 600 | MIAMI | FL | 33136-1128 | MIAMI-DADE | USA | R42CA250629 | STING Activators as Therapy for Cancer | 000 | 2 | NIH | 9/22/2022 | $993,220 |
| | 2022 | 2022 | STINGINN, LLC | 1951 NW 7TH AVE STE 600 | MIAMI | FL | 33136-1128 | MIAMI-DADE | USA | R41AI165061 | Human T cell Lymphotropic Virus Vaccine development | 000 | 1 | NIH | 1/24/2022 | $299,860 |
| | 2022 | 2022 | STINGINN, LLC | 1951 NW 7TH AVE STE 600 | MIAMI | FL | 33136-1128 | MIAMI-DADE | USA | R41AI167270 | Anti-inflammatory Activity of a Systemic STING Inhibitory Non-Nucleotide | 000 | 1 | NIH | 12/17/2021 | $300,000 |
| | 2022 | 2020 | STINGINN LLC | 1951 NW 7TH AVE | MIAMI | FL | 33136-1128 | MIAMI-DADE | USA | R41CA250629 | STING Activators as Therapy for Cancer | 000 | 1 | NIH | 1/24/2022 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $252,064 ) |
| | 2020 | 2020 | STINGINN, LLC | 1951 NW 7TH AVE STE 600 | MIAMI | FL | 33136-1128 | MIAMI-DADE | USA | R41CA250629 | STING Activators as Therapy for Cancer | 000 | 1 | NIH | 9/17/2020 | $252,064 |
|
|
